vs
Side-by-side financial comparison of MIND CTI LTD (MNDO) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.9M, roughly 1.1× MIND CTI LTD). MIND CTI LTD runs the higher net margin — 19.4% vs -507.8%, a 527.2% gap on every dollar of revenue. Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -45.1%).
MIND CTI Ltd. is a global provider of billing and customer care solutions and messaging services for voice, data, video and content services. Headquartered in Yokneam, Israel; the company also has offices in the United States of America, Iaşi in Romania and in Germany.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
MNDO vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.9M | $5.5M |
| Net Profit | $950.0K | $-27.9M |
| Gross Margin | 55.4% | — |
| Operating Margin | 16.5% | -516.0% |
| Net Margin | 19.4% | -507.8% |
| Revenue YoY | — | 171.3% |
| Net Profit YoY | — | -48.3% |
| EPS (diluted) | $0.05 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.9M | $5.5M | ||
| Q3 25 | $16.2M | $0 | ||
| Q2 25 | $11.0M | $2.0M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | $5.2M | $2.0M | ||
| Q3 24 | $16.0M | $1.8M | ||
| Q2 24 | $10.7M | $1.1M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | $950.0K | $-27.9M | ||
| Q3 25 | $3.4M | $-32.7M | ||
| Q2 25 | $2.5M | $-26.9M | ||
| Q1 25 | — | $-21.5M | ||
| Q4 24 | $1.2M | $-18.8M | ||
| Q3 24 | $3.7M | $-25.5M | ||
| Q2 24 | $2.5M | $-20.9M | ||
| Q1 24 | — | $-24.1M |
| Q4 25 | 55.4% | — | ||
| Q3 25 | 48.3% | — | ||
| Q2 25 | 50.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 55.6% | — | ||
| Q3 24 | 50.6% | — | ||
| Q2 24 | 50.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | 16.5% | -516.0% | ||
| Q3 25 | 18.8% | — | ||
| Q2 25 | 21.0% | -1347.1% | ||
| Q1 25 | — | -930.5% | ||
| Q4 24 | 25.4% | -985.8% | ||
| Q3 24 | 22.5% | -1448.4% | ||
| Q2 24 | 22.2% | -1915.4% | ||
| Q1 24 | — | -713.3% |
| Q4 25 | 19.4% | -507.8% | ||
| Q3 25 | 20.9% | — | ||
| Q2 25 | 22.3% | -1353.6% | ||
| Q1 25 | — | -935.2% | ||
| Q4 24 | 23.8% | -929.0% | ||
| Q3 24 | 23.3% | -1427.5% | ||
| Q2 24 | 23.1% | -1882.0% | ||
| Q1 24 | — | -705.4% |
| Q4 25 | $0.05 | $-0.08 | ||
| Q3 25 | $0.16 | $-0.09 | ||
| Q2 25 | $0.12 | $-0.09 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | $0.06 | $-0.07 | ||
| Q3 24 | $0.18 | $-0.10 | ||
| Q2 24 | $0.12 | $-0.09 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.3M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $23.0M | $246.9M |
| Total Assets | $30.2M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.3M | $319.8M | ||
| Q3 25 | $4.5M | $297.3M | ||
| Q2 25 | $4.5M | $312.8M | ||
| Q1 25 | — | $116.6M | ||
| Q4 24 | $4.6M | $139.0M | ||
| Q3 24 | $3.0M | $157.7M | ||
| Q2 24 | $3.0M | $172.7M | ||
| Q1 24 | — | $124.0M |
| Q4 25 | $23.0M | $246.9M | ||
| Q3 25 | $24.3M | $219.0M | ||
| Q2 25 | $24.3M | $248.7M | ||
| Q1 25 | — | $55.1M | ||
| Q4 24 | $24.3M | $71.5M | ||
| Q3 24 | $24.5M | $88.8M | ||
| Q2 24 | $24.5M | $108.9M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | $30.2M | $343.3M | ||
| Q3 25 | $30.7M | $316.6M | ||
| Q2 25 | $30.7M | $333.3M | ||
| Q1 25 | — | $138.4M | ||
| Q4 24 | $30.7M | $160.4M | ||
| Q3 24 | $31.6M | $180.2M | ||
| Q2 24 | $31.6M | $200.4M | ||
| Q1 24 | — | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-26.7M |
| Free Cash FlowOCF − Capex | $4.0M | — |
| FCF MarginFCF / Revenue | 81.0% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 4.20× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-26.7M | ||
| Q3 25 | $3.8M | $-24.2M | ||
| Q2 25 | $2.9M | $-20.2M | ||
| Q1 25 | — | $-22.0M | ||
| Q4 24 | $4.1M | $-18.3M | ||
| Q3 24 | $3.4M | $-21.6M | ||
| Q2 24 | $2.4M | $-21.5M | ||
| Q1 24 | — | $-19.8M |
| Q4 25 | $4.0M | — | ||
| Q3 25 | $3.8M | $-24.3M | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.1M | $-18.3M | ||
| Q3 24 | $3.3M | $-21.6M | ||
| Q2 24 | $2.4M | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | 81.0% | — | ||
| Q3 25 | 23.4% | — | ||
| Q2 25 | 25.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 78.9% | -905.5% | ||
| Q3 24 | 20.8% | -1210.9% | ||
| Q2 24 | 22.1% | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.3% | 2.0% | ||
| Q2 24 | 0.4% | 18.1% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | 4.20× | — | ||
| Q3 25 | 1.12× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.32× | — | ||
| Q3 24 | 0.91× | — | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
